(NewsUSA) - Imagine being able to treat HIV with a simple patch -- it could revolutionize medicine as we know it. For one U.S./Hungarian biopharmaceutical company, Genetic Immunity, this concept may not be far-fetched.
The company, with its DermaVir Patch, hopes to use nanomedicines to amplify a human immune response, allowing the body to fight diseases ranging from cancer to HIV. Currently undergoing Phase II clinical trials, the nanomedicine-containing patch holds great promise for HIV patients. As a topically administered HIV immune therapy, the nanomedicine induces the immune system to recognize and kill HIV-infected cells. This new system contains two innovative components, the nanomedicine vaccine and the topical administration. The DermaVir patch delivers the vaccine as nanoparticles, which is taken to the lymph nodes. There, the vaccine induces a strong immune response.
Today's HIV treatments, antiretroviral drugs, can only delay the onset of AIDS symptoms. The drugs produce uncomfortable side effects, and patients can develop resistance. Treatment must be received at least once daily.
In contrast, the DermaVir Patch promises to amplify the immune system, helping the body's own defenses attack and kill HIV-infected cells, and develop an immune response toward the devastating virus. In trials, patients have not experienced resistance. So far, the DermaVir Patch has not caused toxic reactions in any patient. It can be used with existing therapies. Furthermore, with the DermaVir Patch, patients should not need to receive treatments more than nine times per year.